A Phase 2 interventional study of DB-1311/BNT324 and BNT327 in Solid Tumors, sponsored by DualityBio Inc.. Recruiting at 37 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by DualityBio Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 290 studies in Squamous Cell Carcinoma of Head and Neck with a site in China — 171 open to participants now, 205 under way, 25 of them phase 3. Squamous Cell Carcinoma of Head and Neck · China.
Among the 290 studies in Squamous Cell Carcinoma of Head and Neck with a site in China, this one is the 6th largest by planned enrollment of the 265 interventional ones that give a count, is one of 37 that started in 2025, is one of 139 in phase 2, reaches primary completion later than 193 of the 204 other live ones, and was the 204th registered.
2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →171 of the 290 studies in Squamous Cell Carcinoma of Head and Neck with a site in China are open now. Recruiting first, the newest first:
Taizhou Mabtech Pharmaceutical Co.,Ltd · Sites in China
Ages 18+
Ji Dongmei · Sites in China
Ages 18–70
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–75
West China Hospital · Sites in China
Ages 18–75
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
290 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 172 · Phase 3 37 · Phase 4 2
First in 2005; this study’s year is marked. 37 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 750 is above the median of 48 across 1,653 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 68 across the 265 interventional studies, 136 across the 25 observational. Of the 45 that completed or were terminated, 11 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
89 of 290 have an industry lead sponsor. The 10 most frequent:
DualityBio Inc. is the lead sponsor of 12 studies on the registry; 8 are open to participants now.
DualityBio Inc. has 3 studies filed under Squamous Cell Carcinoma of Head and Neck — fewer than ten, so there is no comparison to draw.
58 of the studies in Squamous Cell Carcinoma of Head and Neck with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06601335Phase 3AkesoA Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | 2027-01 |
| NCT06102395Phase 3Beijing Tongren HospitalEvaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC | 2027-04-30 |
| NCT06772428Phase 3Changchun GeneScience Pharmaceutical Co., Ltd.Nano-crystalline Megestrol Acetate for Adjuvant Treatment in High-risk Head and Neck Squamous Cell Carcinoma After Surgery. | 2027-06-30 |
| NCT06668961Sichuan Baili Pharmaceutical Co., Ltd.A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | 2026-11 |
| NCT06107686MediLink Therapeutics (Suzhou) Co., Ltd.A Study of YL202 in Selected Patients With Advanced Solid Tumors | 2026-11 |
Add all 58 to your calendar (.ics) → With an account.
Among the 290 studies in Squamous Cell Carcinoma of Head and Neck with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
This is a phase II, multicenter, open-label, two-part trial designed to evaluate the safety and preliminary efficacy of DB-1311 in combination with BNT327 or DB-1311 in combination with DB-1305 in targeted participants.
Participants with recurrent, progressive as well as advanced, metastatic hepatocellular carcinoma (HCC), cervical cancer (CC), melanoma, head and neck squamous cell carcinoma (HNSCC), platinum-resistant ovarian cancer (PROC), non-small cell lung cancer (NSCLC), platinum-sensitive ovarian cancer (PSOC), pancreatic ductal carcinoma (PDAC), breast cancer, colorectal cancer (CRC), or metastatic castration resistant prostate cancer (mCRPC) are eligible to participate in the trial.
The criteria were revised on the registry on Oct 29, 2026. See what changed
Key Inclusion Criteria:
Has adequate treatment prior to the first dose of trial treatment.
For breast cancer (Part 2 Arm 8 only):
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Escalating combination dose levels of DB-1311/BNT324 and BNT327 to define RP2D (Recommended Phase 2 Dose) and RP2D-1 in target population.
Drug: DB-1311/BNT324 · Drug: BNT327
Escalating combination dose levels of DB-1311/BNT324 and BNT327 to define RP2D and RP2D-1 in target population.
Drug: DB-1311/BNT324 · Drug: BNT327
Escalating combination dose levels of DB-1311/BNT324 and DB-1305/BNT325 to define RP2D and RP2D-1 in target population.
Drug: DB-1311/BNT324 · Drug: DB-1305/BNT325
In participants with unresectable advanced/metastatic HCC
Drug: DB-1311/BNT324 · Drug: BNT327
In participants with unresectable advanced/ metastatic CC
Drug: DB-1311/BNT324 · Drug: BNT327
In participants with unresectable advanced/metastatic melanoma
Drug: DB-1311/BNT324 · Drug: BNT327
In participants with recurrent/metastatic HNSCC
Drug: DB-1311/BNT324 · Drug: BNT327
In participants with advanced/unresectable metastatic NSCLC
Drug: DB-1311/BNT324 · Drug: DB-1305/BNT325
In participants with unresectable advanced/metastatic PSOC
Drug: DB-1311/BNT324 · Drug: BNT327
In participants with unresectable advanced/metastatic PDAC
Drug: DB-1311/BNT324 · Drug: BNT327
In participants with unresectable advanced/metastatic breast cancer
Drug: DB-1311/BNT324 · Drug: BNT327
In participants with unresectable advanced/metastatic CRC
Drug: DB-1311/BNT324 · Drug: BNT327
In participants with unresectable advanced/metastatic mCRPC
Drug: DB-1311/BNT324 · Drug: BNT327
Drug page: Elfetabart Drozuntecan
Administered I.V.
Administered I.V.
Administered I.V.
Part 1: Number of participants with Dose Limiting Toxicities (DLTs).
Time frame: During the DLT evaluation period, i.e., the time of initiation of the first dose of investigational medicinal product (IMP) up to 21 days
Part 1: Treatment-emergent adverse events (TEAEs) and treatment-emergent serious AE (TESAEs)
Time frame: up to follow up period, e.g. up to 72 months.
Part 2: Objective response rate (ORR), defined as the proportion of participants in whom a confirmed Complete response (CR) or PR is observed as best overall response by arm and dose level. (Arm 1-9).
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
ORR, defined as the proportion of participants in whom a confirmed CR or PR is observed as best overall response (per PCWG3-modified RECIST v1.1 as assessed by investigator) (Arm 10).
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Part 1: ORR, defined as the proportion of participants in whom a confirmed CR or PR is observed as best overall response (per RECIST 1.1 based on the investigator's assessment).
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Part 1 and 2: Duration of response (DoR) per RECIST 1.1 (Arm 1-9) and per PCWG3-modified RECIST v1.1 (Arm 10) based on the investigator's assessment.
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Part 1 and 2: Overall survival (OS)
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Part 1 and 2: Disease-control rate (DCR) per RECIST 1.1 (Arm 1-9) and per PCWG3-modified RECIST v1.1 (Arm 10) based on the investigator's assessment.
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Part 1 and 2: Time to response (TTR) per RECIST 1.1 (Arm 1-9) and per PCWG3-modified RECIST v1.1 (Arm 10) based on the investigator's assessment.
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Part 1 and 2: Progression-free survival (PFS) per RECIST 1.1 (Arm 1-9) and per PCWG3-modified RECIST v1.1 (Arm 10) based on the investigator's assessment.
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Part 1: Cancer antigen 125 (CA-125) response rate assessed per Gynecological Cancer Intergroup (GCIG) criteria in participants with platinum-resistant ovarian cancer (PROC).
Time frame: From the time of initiation of the first dose of IMP to end of Part 1
Part 1 and 2: Cancer antigen 125 (CA-125) response rate assessed per Gynecological Cancer Intergroup (GCIG) criteria in participants with PROC.
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Part 2: Prostate-specific antigen (PSA)-based endpoints PSA50 response rate in participants with mCRPC (Arm 10).
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Part 2: Prostate-specific antigen (PSA)-based endpoints PSA90 response rate in participants with mCRPC (Arm 10).
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Part 2: Prostate-specific antigen (PSA)-based endpoints time to PSA progression in participants with mCRPC (Arm 10).
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Part 2: Prostate-specific antigen (PSA)-based endpoints duration of PSA response in participants with mCRPC (Arm 10).
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Part 2:Treatment-emergent adverse events (TEAEs) and treatment-emergent serious AE (TESAEs)
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Part 1 and 2: Maximum observed concentration (Cmax) of DB-1311/BNT324 ADC, total antibody and unconjugated P1021 in combination with BNT327.
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Part 1 and 2: Maximum observed concentration (Cmax) of DB-1311/BNT324 ADC, total antibody and unconjugated P1021 in combination with DB-1305/BNT325.
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Part 1 and 2: Time to reach maximum observed concentration (Tmax) of DB-1311/BNT324 ADC, total antibody and unconjugated P1021 in combination with BNT327.
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Part 1 and 2: Time to reach maximum observed concentration (Tmax) of DB-1311/BNT324 ADC, total antibody and unconjugated P1021 in combination with DB-1305/BNT325.
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Part 1 and 2: Area under the concentration-time curve from time 0 extrapolated to infinity (AUCinf) of DB-1311/BNT324 ADC, total antibody and unconjugated P1021 in combination with BNT327.
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Part 1 and 2: Area under the concentration-time curve from time 0 extrapolated to infinity (AUCinf) of DB-1311/BNT324 ADC, total antibody and unconjugated P1021 in combination with DB-1305/BNT325.
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Part 1 and 2: Terminal elimination half-life (t1/2) of DB-1311/BNT324 total ADC, total antibody and unconjugated P1021 in combination with BNT327.
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Part 1 and 2: Terminal elimination half-life (t1/2) of DB-1311/BNT324 ADC, total antibody and unconjugated P1021 in combination with DB-1305/BNT325.
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Part 1 and 2: Anti-drug antibody (ADA) prevalence: the proportion of participants who are ADA positive at any point in time (at baseline and post-baseline).
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Part 1 and Part 2: ADA incidence: the proportion of participants having treatment-emergent ADA.
Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Jun 2030, 59 months after the start.
Of 68 industry-sponsored phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's planned 59 months is above that.
Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pumitamig
Squamous Cell Carcinoma of Head and Neck →
DualityBio Inc.